Book Description:
Immunotherapy is a medical term defined as "treatment of disease by inducing, enhancing, or suppressing an immune response". Immunotherapies are designed to elicit or amplify an immune response and are classified as activation immunotherapies. Immunotherapies designed to reduce, suppress or more appropriately direct an existing immune response, as in cases of autoimmunity or allergy, are classified as suppression immunotherapies. This new book reviews research on immunotherapies including antifungal immunotherapy; active and specific immunotherapeutical strategies for the prevention and treatment of cancer; allergen immunotherapy; dendritic cell/tumor fusion cell vaccine in cancer therapy and CRLA-4 inhibition in malignant melanoma.

We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.

Table of Contents:
Preface

Chapter 1. Antifungal Immunotherapy: A Reality Check, pp. 1-76
(Mawieh Hamad, Khaled Abu-Elteen, JMS Medicals, Amman, Jordan, and Hashemite University, Zarqa, Jordan)

Chapter 2. Cancer: Recent Development of Cell-Based Immunotherapy, pp. 77-129
(Amedeo Amedei, Mario Milco D’Elios, University of Florence, Florence, Italy, and others)

Chapter 3. Allergen Immunotherapy: Current Approaches for Management of Allergic Rhinitis and Asthma, pp. 131-157
(Naveen Arora, Neetu Kukreja, Smitha Nair, S.N. Gaur, B.P. Singh, Institute of Genomics and Integrative Biology (CSIR), Delhi, India, and others)

Chapter 4. Dendritic Cell/Tumor Fusion Cell Vaccine in Cancer Therapy, pp. 159-174
(Jia-Ming Chang, Yi-Ru Lee, Kai-ling Huang, Development Center for Biotechnology, Taipei County, Taiwan, ROC, and others)

Chapter 5. CTLA-4 Inhibition in Malignant Melanoma: A New Promising Immunotherapy Target, pp. 175-180
(Tanguy Metz, Wolfram Fink and Pierre Vereecken, Department of Dermatology, CHU-Brugmann, Brussels, Belgium)

Chapter 6. Immunotherapy with IG-Derived Peptides in Systemic Lupus Erythematosus, pp. 181-200
(Antonio La Cava,Division of Rheumatology, Dept. of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California)

Chapter 7. Cancer Immunotherapy and Tumor Escape, pp. 201-221
(Masoud H. Manjili, Maciej Kmieciak, VCU Massey Cancer Center, Commonwealth Foundation for Cancer Research)*

Index